L-ficolin, one of the complement lectins found in human serum, is a novel pattern recognition molecule that can specifically bind to microbial carbohydrates, thereby activating the lectin complement pathway and mounting a protective innate immune response. However, little is known about the role of L-ficolin during viral infections in vivo. In the present study, we used a mouse model of influenza A virus infection to demonstrate that the administration of exogenous L-ficolin or ficolin A (FCNA – an L-ficolin-like molecule in the mouse) is protective against the virus. Furthermore, FCNA-null mice have a greatly increased susceptibility to infection with the influenza A virus. Moreover, we found recombinant human L-ficolin inhibited influenza A virus entry into Madin-Darby canine kidney cells. More importantly, L-ficolin can recognize and bind hemagglutinin (HA) and neuraminidase (NA) glycoproteins and different subtypes of influenza A virus, and these interactions can be competitively inhibited by N-acetyl-D-glucosamine. In addition, the binding of L-ficolin and FCNA may lead to the activation of the lectin complement pathway. To our knowledge, this is the first report demonstrating that L-ficolin can block influenza virus infections both in vitro and in vivo using FCNA-knockout mice, possibly by interacting with the carbohydrates of HA and NA. Therefore, these data may provide new immunotherapeutic strategies based on the innate immune molecule L-ficolin against the influenza A virus.

Keywords:
Complement, L-ficolin, Influenza infection, Hemagglutinin, Neuraminidase, Glycoprotein
1.
Fujita T: Evolution of the lectin-complement pathway and its role in innate immunity. Nat Rev Immunol 2002;2:346–353.
2.
Fujita T, Matsushita M, Endo Y: The lectin-complement pathway – its role in innate immunity and evolution. Immunol Rev 2004;198:185–202.
3.
Matsushita M, Endo Y, Taira S, Sato Y, Fujita T, et al: A novel human serum lectin with collagen- and fibrinogen-like domains that functions as an opsonin. J Biol Chem 1996;271:2448–2454.
4.
Sugimoto R, Yae Y, Akaiwa M, Kitajima S, Shibata Y, et al: Cloning and characterization of the Hakata antigen, a member of the ficolin/opsonin p35 lectin family. J Biol Chem 1998;273:20721–20727.
5.
Endo Y, Sato Y, Matsushita M, Fujita T: Cloning and characterization of the human lectin P35 gene and its related gene. Genomics 1996;36:515–521.
6.
Lynch NJ, Roscher S, Hartung T, Morath S, Matsushita M, et al: L-ficolin specifically binds to lipoteichoic acid, a cell wall constituent of Gram-positive bacteria, and activates the lectin pathway of complement. J Immunol 2004;172:1198–1202.
7.
Nahid AM, Sugii S: Binding of porcine ficolin-alpha to lipopolysaccharides from Gram-negative bacteria and lipoteichoic acids from Gram-positive bacteria. Dev Comp Immunol 2006;30:335–343.
8.
Zhang XL, Ali MA: Ficolins: structure, function and associated diseases. Adv Exp Med Biol 2008;632:105–115.
9.
Runza VL, Schwaeble W, Mannel DN: Ficolins: novel pattern recognition molecules of the innate immune response. Immunobiology 2008;213:297–306.
10.
Kwon S, Kim MS, Kim D, Lee KW, Choi SY, et al: Identification of a functionally relevant signal peptide of mouse ficolin A. J Biochem Mol Biol 2007;40:532–538.
11.
Neumann G, Noda T, Kawaoka Y: Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 2009;459:931–939.
12.
Wikramaratna PS, Gupta S: Influenza outbreaks. Cell Microbiol 2009;11:1016–1024.
13.
Smith JH, Nagy T, Barber J, Brooks P, Tompkins SM, et al: Aerosol inoculation with a sub-lethal influenza virus leads to exacerbated morbidity and pulmonary disease pathogenesis. Viral Immunol 2011;24:131–142.
14.
Ghedin E, Sengamalay NA, Shumway M, Zaborsky J, Feldblyum T, et al: Large-scale sequencing of human influenza reveals the dynamic nature of viral genome evolution. Nature 2005;437:1162–1166.
15.
McHardy AC, Adams B: The role of genomics in tracking the evolution of influenza A virus. PLoS Pathog 2009;5:e1000566.
16.
Taira S, Kodama N, Matsushita M, Fujita T: Opsonic function and concentration of human serum ficolin/P35. Fukushima J Med Sci 2000;46:13–23.
17.
Matsushita M, Fujita T: Ficolins and the lectin complement pathway. Immunol Rev 2001;180:78–85.
18.
Asahi Y, Yoshikawa T, Watanabe I, Iwasaki T, Hasegawa H, et al: Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines. J Immunol 2002;168:2930–2938.
19.
Scull MA, Gillim-Ross L, Santos C, Roberts KL, Bordonali E, et al: Avian influenza virus glycoproteins restrict virus replication and spread through human airway epithelium at temperatures of the proximal airways. PLoS Pathog 2009;5:e1000424.
20.
Zhang W, Wang CY, Yang ST, Qin C, Hu JL, et al: Inhibition of highly pathogenic avian influenza virus H5N1 replication by the small interfering RNA targeting polymerase A gene. Biochem Biophys Res Commun 2009;390:421–426.
21.
Krarup A, Sorensen UB, Matsushita M, Jensenius JC, Thiel S: Effect of capsulation of opportunistic pathogenic bacteria on binding of the pattern recognition molecules mannan-binding lectin, L-ficolin, and H-ficolin. Infect Immun 2005;73:1052–1060.
22.
Liu J, Ali MA, Shi Y, Zhao Y, Luo F, et al: Specifically binding of L-ficolin to N-glycans of HCV envelope glycoproteins E1 and E2 leads to complement activation. Cell Mol Immunol 2009;6:235–244.
23.
Fujimori Y, Harumiya S, Fukumoto Y, Miura Y, Yagasaki K, et al: Molecular cloning and characterization of mouse ficolin-A. Biochem Biophys Res Commun 1998;244;796–800.
24.
Ma Y, Chen H, Wang Q, Luo F, Yan J: IL-24 protects against Salmonella typhimurium infection by stimulating early neutrophil Th1 cytokine production, which in turn activates CD8+ T cells. Eur J Immunol 2009;39:3357–3368.
25.
Chen Z, Matsuo K, Asanuma H, Takahashi H, Iwasaki T, et al: Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin and neuraminidase-expressing DNAs. Vaccine 1999;17:653–659.
26.
Wang QL, Pan Q, Ma Y, Wang K, Sun P, et al: An attenuated Salmonella-vectored vaccine elicits protective immunity against Mycobacterium tuberculosis. Vaccine 2009;27:6712–6722.
27.
Sukumar N, Sloan GP, Conover MS, Love CF, Mattoo S, et al: Cross-species protection mediated by a Bordetella bronchiseptica strain lacking antigenic homologs present in acellular pertussis vaccines. Infect Immun 2010;78:2008–2016.
28.
Lee GC, Jeon ES, Kim WS, Le DT, Yoo JH, et al: Evaluation of a rapid diagnostic test, NanoSign® Influenza A/B Antigen, for detection of the 2009 pandemic influenza A/H1N1 viruses. Virol J 2010;7:244.
29.
McSharry JJ, Weng Q, Brown A, Kulawy R, Drusano GL: Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system. Antimicrob Agents Chemother 2009;53:2375–2381.
30.
Drakulovski P, Carcy B, Moubri K, Carret C, Depoix D, et al: Antibodies raised against Bcvir15, an extrachromosomal double-stranded RNA-encoded protein from Babesia canis, inhibit the in vitro growth of the parasite. Infect Immun 2003;71:1056–1067.
31.
Gravelat FN, Doedt T, Chiang LY, Liu H, Filler SG, et al: In vivo analysis of Aspergillus fumigatus developmental gene expression determined by real-time reverse transcription-PCR. Infect Immun 2008;76:3632–3639.
32.
Verfaillie T, Cox E, Goddeeris BM: Immunostimulatory capacity of DNA vaccine vectors in porcine PBMC: a specific role for CpG-motifs? Vet Immunol Immunopathol 2005;103:141–151.
33.
Lu J, Teh C, Kishore U, Reid KB: Collectins and ficolins: sugar pattern recognition molecules of the mammalian innate immune system. Biochim Biophys Acta 2002;1572:387–400.
34.
Skehel JJ, Wiley DC: Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 2000;69:531–569.
35.
Wagner R, Matrosovich M, Klenk HD: Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Rev Med Virol 2002;12:159–166.
36.
Reading PC, Tate MD, Pickett DL, Brooks AG: Glycosylation as a target for recognition of influenza viruses by the innate immune system. Adv Exp Med Biol 2007;598:279–292.
37.
Leikina E, Delanoe-Ayari H, Melikov K, Cho MS, Chen A, et al: Carbohydrate-binding molecules inhibit viral fusion and entry by crosslinking membrane glycoproteins. Nat Immunol 2005;6:995–1001.
38.
Chang WC, Hartshorn KL, White MR, Moyo P, Michelow IC, et al: Recombinant chimeric lectins consisting of mannose-binding lectin and L-ficolin are potent inhibitors of influenza A virus compared with mannose-binding lectin. Biochem Pharmacol 2011;81:388–395.
39.
Job ER, Deng YM, Tate MD, Bottazzi B, Crouch EC, et al: Pandemic H1N1 influenza A viruses are resistant to the antiviral activities of innate immune proteins of the collectin and pentraxin superfamilies. J Immunol 2010;185:4284–4291.
40.
Hartshorn KL, White MR, Voelker DR, Coburn J, Zaner K, et al: Mechanism of binding of surfactant protein D to influenza A viruses: importance of binding to haemagglutinin to antiviral activity. Biochem J 2000;351:449–458.
41.
van Eijk M, White MR, Batenburg JJ, Vaandrager AB, van Golde LM, et al: Interactions of influenza A virus with sialic acids present on porcine surfactant protein D. Am J Respir Cell Mol Biol 2004;30:871–879.
42.
Cedzynski M, Nuytinck L, Atkinson AP, St Swierzko A, Zeman K, et al: Extremes of L-ficolin concentration in children with recurrent infections are associated with single nucleotide polymorphisms in the FCN2 gene. Clin Exp Immunol 2007;150:99–104.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.